Trisymbiotic IP company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

About Trisymbiotic IP

Trisymbiotic IP provides solutions through licensing of intellectual property. The company solutions by creating small nodes around the world in the form of underground silos, allowing for the proliferation of Hyper Micro Data Centers, IoT Node Centers, and High-Performance Computing centers with an 80% energy reduction over current facilities. Allowing world parity in IoT, 5G, and, especially Cryptocurrency.

Trisymbiotic IP Headquarter Location

Austin, Texas,

United States

512 800 6381

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Trisymbiotic IP

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Trisymbiotic IP is included in 1 Expert Collection, including Conference Exhibitors.


Conference Exhibitors

5,302 items

Latest Trisymbiotic IP News

10:18 EDT Amicrobe, Inc., Developer of Novel Synthetic Biologics, Adds Fifth U.S. Patent to Intellectual Property Portfolio

Apr 26, 2022

News provided by Share this article Share this article U.S. Patent No. 11,285,189 is focused on safety in the prevention and treatment of infections with Amicidin technology. CARLSBAD, Calif., April 26, 2022 /PRNewswire/ -- Today, Amicrobe, Inc. announced the issue of U.S. Patent No. 11,285,189, entitled "Compositions and uses of locally applied antimicrobials with enhanced performance and safety." Amicidins are synthetic biologics designed to be safe for individuals and the environment – this new patent acknowledges the Company's inventive approach in achieving this important goal. Amicrobe's fifth U.S. patent brings its intellectual property portfolio to 26 issued / allowed patents worldwide, further protecting its Amicidin technology platform and innovative product candidates. From the relentless rise of antibiotic-resistant bacteria to the rapid devastation caused by COVID-19, microbes continue to demonstrate their ability to wreak havoc on our lives and livelihoods. Amicrobe develops novel synthetic biologics, called Amicidins, designed to make the world safer from harmful microbes. Amicidins combine physical (materials) properties and microbicidal activity to combat pathogenic bacteria, fungi, and viruses. It is expected that Amicidins will create new products and improve old ones across multiple industries from breakthrough therapeutics to enhanced consumer health to safer food and water. Amicrobe's two lead investigational products, Amicidin-α Surgical Gel and Amicidin-β Solution, are engineered for local application to exposed tissues in order to prevent and treat life-threatening infections associated with surgery and trauma. Amicidin-α Surgical Gel is targeting a Phase 1/2a clinical trial in mastectomy. Amicidin-β Solution is targeting a Phase 1/2a trial in orthopedic hardware-related infections. The safety of Amicidins should allow application in abundance. Dr. Michael Bevilacqua, CEO & CSO of Amicrobe stated, "Our intellectual property, technology platform, and nonclinical product development efforts continue to grow stronger by the day. With these achievements now in place, we anticipate that Amicrobe's next phase will include clinical trials, corporate partners, and many new product opportunities." About Amicrobe, Inc. Amicrobe engineers synthetic biologics called Amicidins. Drawing inspiration from nature, they possess desirable physical properties and potent antimicrobial activity. Physical properties make them versatile; microbicidal activity brings protection against bacteria, fungi, and viruses. Like nature's antimicrobials, Amicidins are designed to be fully biodegradable and safe for the environment. Amicrobe is headquartered in Carlsbad, California. For more information, please visit . Contact:

  • Where is Trisymbiotic IP's headquarters?

    Trisymbiotic IP's headquarters is located at Austin.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.